Clinical trial
Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
NCT00070564 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- November 30, 2003
- Completion date
- January 31, 2027
- Enrollment
- 3,294 (actual)
- Sites
- 542
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer